FNY Investment Advisers LLC raised its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 160.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 477,823 shares of the biopharmaceutical company’s stock after purchasing an additional 294,323 shares during the quarter. FNY Investment Advisers LLC owned 0.46% of Revance Therapeutics worth $1,452,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of the business. Arizona State Retirement System lifted its stake in Revance Therapeutics by 27.6% during the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,996 shares in the last quarter. Sei Investments Co. increased its stake in Revance Therapeutics by 52.5% during the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 7,628 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Revance Therapeutics by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 7,890 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Revance Therapeutics by 29.4% in the second quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 9,601 shares during the period. Finally, FORA Capital LLC purchased a new position in shares of Revance Therapeutics in the third quarter valued at approximately $54,000. Institutional investors and hedge funds own 97.70% of the company’s stock.
Analyst Ratings Changes
RVNC has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays cut their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. StockNews.com began coverage on Revance Therapeutics in a report on Monday. They issued a “hold” rating for the company. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.39.
Revance Therapeutics Stock Up 1.2 %
NASDAQ RVNC opened at $3.29 on Tuesday. The stock has a market capitalization of $343.44 million, a P/E ratio of -1.70 and a beta of 0.86. Revance Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $7.56. The firm has a 50-day moving average price of $3.61 and a 200 day moving average price of $4.54.
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, equities research analysts expect that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
See Also
- Five stocks we like better than Revance Therapeutics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Basic Materials Stocks Investing
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Buy P&G Now, Before It Sets A New All-Time High
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.